Identifying patients most likely to benefit from SGLT2 inhibition may be facilitated by pragmatic pharmacodynamic and volume-status biomarkers adapted from diabetes, chronic kidney disease and decongestion studies, pending validation in cirrhosis [163,164]. This evidence concerns the gene SLC5A2 and diabetes mellitus.